Z Contains A Cyclopentyl Or Cyclopentene Ring Patents (Class 514/530)
-
Publication number: 20090092654Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.Type: ApplicationFiled: December 10, 2008Publication date: April 9, 2009Applicants: QLT Plug Delivery, Inc., ForSight Labs, LLC., a California corporationInventors: Eugene de Juan, JR., Cary Reich, Stephen Boyd, Hanson G. Gifford, III, Mark Deem
-
Publication number: 20090088473Abstract: A method for developing Prostaglandin F2? analogs for enhancing and sustaining the growth of eye lashes. The exemplary method first provides a method for determining the ability of a FP receptor agonist test compound having unknown hair growth ability to induce hair growth in its free acid form. The test compound may then be provided in its amide, or slowly hydrolyzing form and ester form, or rapidly hydrolyzing form to determine the relative hydrolysis rate within corneal tissue. Depending upon its hair growth ability and relative hydrolysis rates, the Prostaglandin F2? analog in one or more forms may be used an ingredient in a binary cosmetic prodrug designed for enhancing and sustaining the growth of eye lashes.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: CAYMAN CHEMICAL COMPANYInventor: Kirk M. Maxey
-
Publication number: 20090088366Abstract: The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione.Type: ApplicationFiled: September 24, 2008Publication date: April 2, 2009Applicant: NitroMed, Inc.Inventors: David S. Garvey, Ricky D. Gaston, Inigo Saenz de Tejada, Sang William Tam, Manuel Worcel
-
Publication number: 20090082442Abstract: The present application describes deuterium-enriched lubiprostone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090074844Abstract: The present invention relates to a blood concentration regulation type percutaneous absorption preparation, which comprises an ester form of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoic acid and a base for external preparations. The blood concentration regulation type percutaneous absorption preparation of the present invention can stably maintain blood concentration of the active form of the present invention and is safe since there are no side effects. Therefore, it can be used as a percutaneous absorption preparation which can be persistently administered.Type: ApplicationFiled: April 27, 2006Publication date: March 19, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akio Nishiura, Hikaru Sugihara, Harumi Arai, Toshiya Kanaji
-
Publication number: 20090062561Abstract: The present application describes deuterium-enriched latanoprost, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 25, 2008Publication date: March 5, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090062296Abstract: Nitroderivatives of prostaglandin amides having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.Type: ApplicationFiled: June 28, 2006Publication date: March 5, 2009Inventors: Francesca Benedini, Valerio Chiroli, Wesley Kwan Mung Chong, Achim Hans-Peter Krauss, Michael Ross Niesman, Ennio Ongini
-
Patent number: 7498360Abstract: A novel method and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss are described. The treatment is based on the administration of a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may involve the use of pumps, gels, or slow release drug inserts.Type: GrantFiled: January 15, 2002Date of Patent: March 3, 2009Assignee: Synphora ABInventors: Helge Rask-Andersen, Johan Stjernschantz
-
Publication number: 20090054442Abstract: A method is provided of treating an eye with ophthalmologically active compounds, particularly with intra-ocular pressure lowering (IOP) compounds, where a dose of 5-15 microliters is delivered at a standard concentration.Type: ApplicationFiled: October 28, 2008Publication date: February 26, 2009Inventors: BEN Z. COHEN, NIGEL KELLY
-
Publication number: 20090041869Abstract: The present invention discloses Resistance Management (RM) practices that are critical to safeguard Bacillus thuringiensis as a natural resource and sustain genetically modified corn expressing Bt toxins as a suitable method for ECB and WCRW management. A useful tool in developing RM strategies is to develop laboratory selected colonies that exhibit high levels of resistance to a particular toxin. The availability of selected strains allows determination of the genetic expression of resistance (i.e., dominant vs. recessive, autosomal vs. sex-linked) and whether or not the resistance mechanism is specific for a given toxin. In addition, the availability of resistant strains will allow estimation of the particular resistance allele frequency in the field, and provides a tool to identify the biochemical and physiological basis of resistance and a means to develop molecular probes to monitor the evolution of resistance in the field.Type: ApplicationFiled: October 15, 2008Publication date: February 12, 2009Applicant: PIONEER HI-BRED INTERNATIONAL, INC.Inventor: DANIEL J. COSGROVE
-
Publication number: 20090030055Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: ApplicationFiled: May 24, 2007Publication date: January 29, 2009Inventors: Thomas Nelson, Daniel L. Alkon
-
Publication number: 20090030076Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.Type: ApplicationFiled: September 15, 2008Publication date: January 29, 2009Inventors: Ennio Ongini, Valerio Chiroli, Francesca Benedini, Piero Del Soldato
-
Publication number: 20090022787Abstract: Provided is a pharmaceutical composition comprising a 11-deoxy-prostaglandin compound represented by formula (I): and a fatty acid ester. By mixing the compound of formula (I) and a fatty acid ester, the compound of formula (I) will be stabilized.Type: ApplicationFiled: July 16, 2008Publication date: January 22, 2009Applicants: R-TECH UENO, LTD., SUCAMPO AGInventors: Yasuhiro HARADA, Junichi Kawasaki, Yoshie Nishimura, Ryuji Ueno
-
Publication number: 20090018092Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.Type: ApplicationFiled: March 16, 2005Publication date: January 15, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Bruce D Hammock, Takaho Watanabe, Seung Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
-
Publication number: 20080319066Abstract: The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers.Type: ApplicationFiled: August 26, 2008Publication date: December 25, 2008Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Eliezer FLESCHER, Yoel Kashman, Dorit Reischer, Shiri Shimony
-
Publication number: 20080312321Abstract: Therapeutic compounds are disclosed herein.Type: ApplicationFiled: August 14, 2008Publication date: December 18, 2008Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Robert M. Burk
-
Publication number: 20080306072Abstract: The present invention relates to compounds selected from the group consisting of 14-0-[((Mono- or dialkylamino)-cycloalkylsulfanyl- or -cycloalkyl-oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, 14-O-[((Cycloalkyl- or heterocyclylamino)-cy-cloalkylsulfanyl- or -cycloalkyl-oxy)-acetyl, -thioaceyl or -imino-oxy]-mutilins, 14-O-[((Heterocyc-N-yl-cycloalkyl)-sulfanyl- or -oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, 14-O-[(((Mono- or dialkylamino)-cycloalkyl)-alkylsulfanyl- or -alkyl-oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, 14-O-[(((Cycloalkyl- or heterocyclylamino)-cycloalkyl)-alkylsulfanyl- or -alkyl-oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, and 14-O-[((Heterocyc-N-yl-cycloalkyl)-alkylsulfanyl- or -alkyl-oxy)-acetyl, -thioacetyl or -imino-oxy]-mutilins, and their use as pharmaceuticals.Type: ApplicationFiled: July 26, 2006Publication date: December 11, 2008Applicant: NABRIVA THERAPEUTICS FORSCHUNGS GMBHInventors: Rosemarie Mang, Heinz Berner
-
Patent number: 7459583Abstract: The present invention relates to a novel method for providing a cathartic effort to a patient in need of cathartic induction, which comprises administering to the patient a cathartic-inducing effective amount of halogenated bioactive lipid comprising the following patial structure (I): The method is useful for relieving or preventing constipation, and also for cleansing the gastrointestinal tract.Type: GrantFiled: July 28, 2005Date of Patent: December 2, 2008Assignee: Sucampo AGInventor: Ryuji Ueno
-
Publication number: 20080286291Abstract: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.Type: ApplicationFiled: September 12, 2005Publication date: November 20, 2008Inventors: Brij B. Saxena, Premila Rathnam
-
Patent number: 7452556Abstract: The present invention relates to compositions for the treatment of pilosebaceous gland inflammations, especially of the hair follicle and its appendages, in particular of Acne Vulgaris and Folliculitis, comprising as active ingredient AIF or chemical compounds which finally release AIF, or combinations of aluminum and fluoride salts which finally release AIF. AIF in accordance with the present invention relates to Aluminum fluoride (Aluminum Trifluoride; Aluminum Fluoride), CAS No 7784-18-1, EINECS No. 232-051-1, having an empirical formula of AIF3. Said compositions have, inter alia, pharmaceutical, cosmetic or quasi-cosmetic properties. The present invention also relates to the use of said compositions in said treatment, and to methods for the treatment of pilosebaceous gland inflammations with said compositions.Type: GrantFiled: October 2, 2002Date of Patent: November 18, 2008Assignee: Medidermis Ltd.Inventor: Avi Dascalu
-
Publication number: 20080268020Abstract: Cationic ophthalmic oil-in-water type emulsions, include colloid particles having an oily core surrounded by an interfacial film. The emulsion includes at least one cationic agent and at least one non ionic surfactant, the oily core including a prostaglandin selected from the group consisting essentially of latanoprost, unoprostone isopropyl, travoprost, bimatoprost, tafluprost, 8-isoprostaglandinE2, or a mixture thereof, for treating ocular hypertension and/or glaucoma. These emulsions have the property to increase the chemical stability of prostaglandins.Type: ApplicationFiled: October 10, 2006Publication date: October 30, 2008Applicant: Novagali Pharma SAInventors: Betty Philips, Severine Bague, Laura Rabinovich-Guilatt, Gregory Lambert
-
Publication number: 20080249166Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: ApplicationFiled: June 9, 2008Publication date: October 9, 2008Applicant: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Daniela Carmen Oniciu
-
Publication number: 20080226753Abstract: The present invention discloses Resistance Management (RM) practices that are critical to safeguarding Bacillus thuringiensis as a natural resource and to sustaining genetically modified crops that express Bt toxins for managing ECB and WCRW. The methods involve blending seed transformed with a nucleic acid encoding a different pesticidal protein, where both proteins target the same pest, but use different modes of pesticidal action. The seed can be also treated with pesticidal agents.Type: ApplicationFiled: March 29, 2005Publication date: September 18, 2008Applicant: PIONEER HI-BRED INTERNATIONAL, INC.Inventor: Daniel J. Cosgrove
-
Patent number: 7425651Abstract: The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers.Type: GrantFiled: December 1, 2004Date of Patent: September 16, 2008Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Eliezer Flescher, Yoel Kashman, Dorit Reischer, Shiri Shimony
-
Publication number: 20080194532Abstract: Compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, where composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, and the ophthalmic emulsions being are useful for eye care or for the treatment of eye conditions.Type: ApplicationFiled: January 30, 2008Publication date: August 14, 2008Applicant: NOVAGALI PHARMA SAInventors: Laura Rabinovich-Guilatt, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Patent number: 7407987Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.Type: GrantFiled: November 30, 2006Date of Patent: August 5, 2008Assignee: Duke UniversityInventors: Mitchell Anthony deLong, John McMillan McIver, Robert Scott Youngquist
-
Publication number: 20080181867Abstract: The present invention relates to new processes for the preparation of oil-in-water emulsions useful in ophthalmic applications. In particular, processes are provided that include preparing a pre-concentrate of the oil-in-water emulsion, and diluting the pre-concentrate obtained to form the desired oil-in-water emulsion. The present invention also provides pharmaceutical compositions comprising an oil-in-water emulsion prepared by an inventive process, and methods of using these compositions for the treatment of an eye disease or condition.Type: ApplicationFiled: December 21, 2007Publication date: July 31, 2008Applicant: NOVAGALI PHARMASAInventors: Gregory LAMBERT, Frederic Lallemand, Laura Rabinovich-Guilatt, Pascal Candillon, Julien Lafosse
-
Publication number: 20080171788Abstract: The invention relates to a medicament for IBS, which comprises a dual antagonist for 5-HT2B and 5-HT7 receptors having selective binding affinities for 5-HT2B and 5-HT7 receptors. The pharmaceutical composition of the invention is useful as a drug which is excellent in the therapeutic effect on IBS and shows lessened side effects occurring in the existing remedies for IBS, because it showed good pharmacological actions in comparison with the case of independently using a 5-HT2B receptor antagonist having selective binding affinity for 5-HT2B receptor or a 5-HT7 receptor antagonist having selective binding affinity for 5-HT7 receptor.Type: ApplicationFiled: February 7, 2006Publication date: July 17, 2008Inventors: Shinobu Akuzawa, Hiroyuki Ito, Toshihiro Watanabe, Hiroyoshi Yamada
-
Publication number: 20080167374Abstract: The invention provides pesticide compositions and methods of use. In particular, pesticide compositions comprises a photolabile pesticide and a UV absorbent.Type: ApplicationFiled: November 5, 2007Publication date: July 10, 2008Applicant: Loveland Products, Inc.Inventors: Chris Stickler, Randall Worthley
-
Patent number: 7388029Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.Type: GrantFiled: May 26, 2005Date of Patent: June 17, 2008Assignee: Duke UniversityInventors: Mitchell Anthony DeLong, John McMillan McIver, Robert Scott Youngquist
-
Publication number: 20080112992Abstract: The invention relates to a method for controlling the application of an insecticide on a surface, which comprises the use of an insecticide composition including a pH indicator colorant in an aqueous medium changing the colorless after drying in the air on said surface, and the recoloration of the insecticide composition by remoistering selected areas of the surface to be checked.Type: ApplicationFiled: September 6, 2007Publication date: May 15, 2008Applicant: FLIT.S.A.Inventors: Hisham Mohamed Mahgoub, Amina Ahmed Mahmoud Fahmy
-
Publication number: 20080102102Abstract: The invention provides methods and compositions comprising an anti-cholinergic agent for decreasing saliva production and treating sialorrhea.Type: ApplicationFiled: January 19, 2006Publication date: May 1, 2008Applicant: NEUROHEALING PHARMACEUTICALS, INC.Inventors: Marcelo Merello, Neal M. Farber, Eyal S. Ron
-
Patent number: 7365097Abstract: Disclosed herein is the cosmetic use, as a desquamating agent, of at least one (dihydro)jasmonic acid derivative of a given formula. Further disclosed herein is a cosmetic method for smoothing the visible and/or tactile irregularities of the skin surface, for example, for smoothing wrinkles and fine lines and/or skin spots and/or smoothing the skin, comprising topically applying, to the skin, a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative and glycerine. Other embodiments disclosed herein are novel (dihydro)jasmonic acid derivatives.Type: GrantFiled: July 27, 2004Date of Patent: April 29, 2008Assignee: L'Oreal, S.A.Inventors: Michel Neuwels, Maria Dalko
-
Publication number: 20080090780Abstract: A storage stable, efficacious pesticide formulation is provided that is dilutable by the user and contains azadirachtin (AZA) and a pyrethrin or pyrethroid (PYR), and optionally an aprotic solvent and non-ionic, substantially water-free emulsifier. A sufficient amount of the PYR is provided to complex with the AZA A on opposite sides of the molecular structure thereof, thereby preventing rearrangement of the AZA A molecule in the presence of moisture that would result in hydrolysis and decomposition of AZA A. The AZA-PYR combination is sufficiently chemically stable such that less than 10% of the AZA A is decomposed when the formulation is subjected to an accelerated aging test for 30 days at 40° C. in a sealed container. The molar ratio of PYR to AZA A is preferably within the range of 0.5/1-10.5/1, more preferably within the range of 1.5/1-7/1, and most preferably with the range of 3/1-6/1.Type: ApplicationFiled: October 13, 2006Publication date: April 17, 2008Applicant: PBI/GORDON CORPORATIONInventors: Dale R. Sanson, James A. Armbruster
-
Publication number: 20080033036Abstract: The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof.Type: ApplicationFiled: August 12, 2004Publication date: February 7, 2008Inventors: Ryuji Ueno, Tsuyoshi Habe, Takashi Sekida
-
Patent number: 7202275Abstract: The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.Type: GrantFiled: May 10, 2005Date of Patent: April 10, 2007Assignee: Warner Lambert Company LLCInventors: Yuan-Ching P. Chiang, Gary E. Aspnes, Kimberly G. Estep
-
Patent number: 7176238Abstract: The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione.Type: GrantFiled: March 1, 2000Date of Patent: February 13, 2007Assignee: NitroMed Inc.Inventors: David S. Garvey, Ricky D. Gaston, L. Gordon Letts, Inigo Saenz de Tejada, Sang William Tam, Manuel Worcel
-
Patent number: 7163959Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.Type: GrantFiled: November 25, 2003Date of Patent: January 16, 2007Assignee: Pharmacia AktiebolagInventors: Johan Wilhelm Stjernschantz, Bahram Resul
-
Patent number: 7141606Abstract: The invention provides a new use of compounds for formula 1 or 1A or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of insomnia and related disorders.Type: GrantFiled: May 18, 2001Date of Patent: November 28, 2006Assignee: Warner-Lambert CompanyInventors: Justin Stephen Bryans, Leonard Theodore Meltzer
-
Patent number: 7141607Abstract: Methods and compositions for the prophylactic and therapeutic treatment of retinal disorders associated with neovascularization using topical ophthalmic compositions comprising hydroxamic acid matrix metalloproteinase inhibitors such as batimastat.Type: GrantFiled: March 10, 2000Date of Patent: November 28, 2006Assignee: Insite Vision IncorporatedInventors: Erwin Si, Lyle M. Bowman
-
Patent number: 7129272Abstract: Disclosed is a method for treatment of a subject having a disease or condition associated with apoptosis, which comprises administering to the subject an effective amount of a 15-keto-prostaglandin compound represented by the following formula (I):Type: GrantFiled: March 26, 2001Date of Patent: October 31, 2006Assignee: Sucampo AGInventors: Ryuji Ueno, Yukihiko Mashima
-
Patent number: 7084178Abstract: A series of N-cycloalkylcarboxamide derivatives of N-benzyl benzenesulfonamides of Formula I are described. The compounds inhibit ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of ?-amyloid. Pharmaceutical compositions and methods of treatment using these compounds are also disclosed.Type: GrantFiled: November 18, 2004Date of Patent: August 1, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Lawrence R. Marcin, Mendi A. Higgins
-
Patent number: 7074827Abstract: Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.Type: GrantFiled: May 6, 2003Date of Patent: July 11, 2006Assignee: Sucampo AG (USA) Inc.Inventor: Ryuji Ueno
-
Patent number: 7053119Abstract: The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the present invention provides methods and compositions for the improving the therapeutic activity of COX2 inhibitors, comprising administering the COX2 to a subject in combination with a compound that inhibits IKK activity. The present invention further provides compositions that comprise compounds that inhibit IKK and COX2.Type: GrantFiled: February 28, 2003Date of Patent: May 30, 2006Assignees: The Regents of the University of California, Charterhouse Therapeutics Ltd.Inventors: Michael Karin, Pankaj Kapahi
-
Patent number: 7049340Abstract: The invention concerns a neuroprotective and retinoprotective medicine, whereof the active principle is selected among a group of compounds consisting of ramipril, ramiprilat or any other ramiprilat derivative capable of releasing it in the organism whereto it is administered. Said medicine is used for prevention, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies involving a vascular factor, in particular glaucomatous neuropathy, degenerative choriopathy of strong myopia, age-related maculopathy, serous central chorioretinopathy, hereditary dystrophy of the retina and retinal venous occlusions. It almost invariably improves the visual function (acuity and visual field).Type: GrantFiled: June 16, 2000Date of Patent: May 23, 2006Inventor: Raouf Rekik
-
Patent number: 7019031Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.Type: GrantFiled: October 23, 2001Date of Patent: March 28, 2006Assignee: The Arizona Disease Control Research CommissionInventors: Seth D. Rose, Scott R. Lefler, Steven R. Ottersberg, Ann Y. Kim, Karl J. Okolotowicz, Rosemarie F. Hartman
-
Patent number: 6982283Abstract: Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.Type: GrantFiled: May 1, 2002Date of Patent: January 3, 2006Assignee: Sucampo AGInventor: Ryuji Ueno
-
Patent number: 6981684Abstract: An apparatus for supporting a metal post while it is being driven into the ground utilizes a platen base and a guide member which is rotatably joined to the base for holding the post in a steady condition while the post is being driven into the ground. Because the guide member is rotatably joined to the base member, the rotational position of a post positioned within the guide member can be significantly altered with respect to the base.Type: GrantFiled: July 12, 2004Date of Patent: January 3, 2006Inventor: George William Wadsworth
-
Patent number: 6972294Abstract: Disclosed are novel compounds of formula (I) wherein A1, A2, Ar, R5, R6, R8, M, Q, Y, Z, k, m and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR). Such conditions include diabetes and obesity.Type: GrantFiled: April 18, 2000Date of Patent: December 6, 2005Assignee: Novo Nordisk, A/SInventors: Anthony Murray, Per Sauerberg, Lone Jeppesen, Ingrid Pettersson, Paul Stanley Bury
-
Patent number: RE39609Abstract: The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma It is based, at least in part, on the discovery that 8-iso prostaglandin E2 effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.Type: GrantFiled: February 11, 2002Date of Patent: May 1, 2007Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Steven M. Podos, Thomas W. Mittag, Bernard Becker